Clariant secures FDA approval for bio-based Licocare™ RBW additives in rigid PVC food-contact applications

• FDA approval expands Clariant's Licocare RBW portfolio authorization from polyester to include rigid PVC materials, effective May 7, 2026
• All Licocare RBW grades now FDA-approved for rigid PVC with dual application scope: direct food contact (up to 0.5%) and food processing equipment (up to 1%)
• Combined with existing EFSA authorization, approval strengthens Clariant's position in delivering globally compliant, sustainable food-contact solutions
• Rice bran wax additives offer renewable alternative to fossil-based options while addressing ongoing montan wax supply challenges

MUTTENZ, May 28, 2026 - Clariant has received U.S. Food and Drug Administration (FDA) approval for its bio-based Licocare RBW wax additives for use in rigid polyvinyl chloride (PVC) food-contact applications. The authorization, effective May 7, 2026, extends the company's existing FDA approval beyond polyester materials to include rigid PVC.

The approval covers the complete Licocare RBW product range, including the RBW 100 series, RBW 300 series, and the grades Licocare RBW 360 Vita and RBW 560 Vita. The additives are authorized for use as processing aids, lubricants, release agents, and slip additives in single- and repeat-use rigid PVC applications across all food types, except for infant formula and human milk contact.

For direct food-contact applications, the additives are approved at levels up to 0.5% by weight under conditions of use C through H, with a temperature maximum of 80°C for hot-fill applications. Clariant has also received an Opinion Letter of No Objection (LONO) for repeated use up to 1% concentration in food-contact articles for food processing equipment made of rigid PVC.

The dual authorization enables use across multiple applications, including rigid PVC containers, packaging materials, and food processing equipment components such as conveyor belts, cutting boards, storage containers, seals, and gaskets. The different concentration levels allow formulators to adjust specifications based on their specific application requirements while maintaining regulatory compliance.

The FDA approval adds to Clariant's existing regulatory authorizations for the Licocare RBW portfolio. In February 2026, the EU Commission published authorization based on EFSA's positive opinion for the same product line in PET, PLA, and rigid PVC materials. The company also holds authorization from the Japanese food safety authority. This combination of approvals provides manufacturers with regulatory compliance across major international markets.

"Achieving FDA approval for our Licocare RBW additives in rigid PVC applications demonstrates Clariant's commitment to delivering sustainable solutions that meet the highest regulatory standards across multiple jurisdictions," said Diederik Goyvaerts, Market Manager, Additives at Clariant. "This authorization represents years of dedicated work and opens significant opportunities for manufacturers to transition to renewable alternatives while maintaining full compliance with food safety regulations in both North American and European markets."

Licocare RBW additives are derived from rice bran wax and provide a renewable alternative with substantial carbon footprint reductions compared to conventional fossil-based montan waxes. The industry has experienced supply constraints with montan wax, which is extracted from lignite coal deposits in Germany that are actively depleting. This has resulted in supply disruptions and price increases for manufacturers.

The rice bran wax additives provide processing benefits including lubrication, mold release, nucleation effects, and enhanced dispersion properties. The products are biodegradable and industrially compostable, which supports end-of-life sustainability requirements for packaging materials. The production process avoids the landscape disruption and biodiversity impact associated with lignite mining.

The FDA approval for rigid PVC follows Clariant's approach of securing regulatory authorizations across different materials and regions. With approvals now covering FDA, EFSA, and Japanese authorities, the company has established regulatory compliance for its bio-based Licocare RBW portfolio in key global markets. This provides manufacturers with the regulatory framework needed to implement renewable alternatives in their food-contact application.

Licocare™ IS A TRADEMARK OF CLARIANT.